2025
Estimating the Serotype-Specific Association Between the Concentration of Vaccine-Induced Serum Antibodies and Protection Against Pneumococcal Colonization
Wong A, Warren J, Fitch L, Perniciaro S, Dagan R, Weinberger D. Estimating the Serotype-Specific Association Between the Concentration of Vaccine-Induced Serum Antibodies and Protection Against Pneumococcal Colonization. The Journal Of Infectious Diseases 2025, jiaf106. PMID: 40036886, DOI: 10.1093/infdis/jiaf106.Peer-Reviewed Original ResearchHigher-valent PCVsPneumococcal conjugate vaccinePneumococcal colonizationVaccine-induced serum antibodiesRisk of colonizationSerum immunoglobulin GRandomized controlled trialsConjugate vaccinePCV13Clinical trialsSerum IgGImmune responseVaccinated childrenSevere diseaseVaccine effectivenessSerum antibodiesPCV20Serotype-specificImmunoglobulin GSerotypesColonIndirect protectionIgGVaccineTrialsHost-microbe multiomic profiling identifies distinct COVID-19 immune dysregulation in solid organ transplant recipients
Pickering H, Schaenman J, Phan H, Maguire C, Tsitsiklis A, Rouphael N, Higuita N, Atkinson M, Brakenridge S, Fung M, Messer W, Salehi-rad R, Altman M, Becker P, Bosinger S, Eckalbar W, Hoch A, Doni Jayavelu N, Kim-Schulze S, Jenkins M, Kleinstein S, Krammer F, Maecker H, Ozonoff A, Diray-Arce J, Shaw A, Baden L, Levy O, Reed E, Langelier C. Host-microbe multiomic profiling identifies distinct COVID-19 immune dysregulation in solid organ transplant recipients. Nature Communications 2025, 16: 586. PMID: 39794319, PMCID: PMC11723965, DOI: 10.1038/s41467-025-55823-z.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsOrgan transplant recipientsTransplant recipientsInduction of pro-inflammatory genesSenescent T cellsTransitional B cellsImpaired viral clearanceImmune response to infectionAnti-spike IgG levelsNon-transplanted controlsFeatures of COVID-19Innate immune signaling pathwaysResponse to infectionPro-inflammatory genesSerum chemokinesViral clearanceImmune dysregulationT cellsImmune signaling pathwaysB cellsImmune featuresSex-matchedIgG levelsSevere diseaseTransplantation
2024
Severe Clinical Outcomes Due to Human Adenoviral Respiratory Infections in Hospitalized Immunocompetent Adults
Legakis L, Nguyen D, Bandaranayake T. Severe Clinical Outcomes Due to Human Adenoviral Respiratory Infections in Hospitalized Immunocompetent Adults. Infectious Diseases In Clinical Practice 2024, 32: e1412. DOI: 10.1097/ipc.0000000000001412.Peer-Reviewed Original ResearchSevere adenoviral infectionAdenoviral infectionImmunocompetent patientsClinical outcomesSmoking historyPulmonary diseaseRisk factorsSevere diseaseAdenoviral respiratory infectionUpper respiratory tract infectionRespiratory viral panelAbsence of feverAdult immunocompetent patientsExtracorporeal membrane oxygenationRespiratory tract infectionsSevere clinical outcomesChronic obstructive pulmonary diseasePresence of coinfectionObstructive pulmonary diseasePotential risk factorsCritical careImmunocompetent adultsImmunocompromised patientsImmunocompetent hostsTract infectionsExamining Clinical Features and Severe Neurologic Disease of Parechovirus Infection in Young Infants: A Multistate Cohort Study
Evans A, Singh S, Joshi C, Filkins L, Akkoyun E, Custodio H, Daniels E, Kao C, Richardson K, Carrillo-Marquez M, Borré C, Oliveira C, Espinosa C, Mandelia Y, Mazade M, Kimberlin D. Examining Clinical Features and Severe Neurologic Disease of Parechovirus Infection in Young Infants: A Multistate Cohort Study. Clinical Infectious Diseases 2024, 79: 1479-1486. PMID: 39093815, DOI: 10.1093/cid/ciae400.Peer-Reviewed Original ResearchSevere neurological diseaseLongitudinal follow-up of infantsYoung infantsSevere diseaseViral co-infectionsNon-severe diseaseSpectrum of illnessNeurological diseasesParechovirus infectionLongitudinal follow-upPreterm gestationHPeV infectionClinical seizuresClinical featuresPoor feedingCerebral edemaHuman parechovirusCohort studyU.S. infantsCo-infectionHPeVRespiratory symptomsInfantsSevere casesDiseaseInteractions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic review
Besteman S, Bogaert D, Bont L, Mejias A, Ramilo O, Weinberger D, Dagan R. Interactions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic review. The Lancet Respiratory Medicine 2024, 12: 915-932. PMID: 38991585, DOI: 10.1016/s2213-2600(24)00148-6.Peer-Reviewed Original ResearchRespiratory syncytial virusChildhood respiratory infectionsRespiratory infectionsSyncytial virusStreptococcus pneumoniaeRespiratory syncytial virus vaccineLower respiratory tract infectionsRespiratory tract infectionsSystematic reviewGlobal health burdenYears of ageRSV hospitalisationTract infectionsPneumococcal vaccineSevere diseaseGlobal morbidityEpidemiological associationMonoclonal antibodiesPathogen-pathogen interactionsPneumococciInfectionHealth burdenPathogenesisHost modulationApproaches to disease preventionBacille Calmette-Guérin vaccination to prevent febrile and respiratory illness in adults (BRACE): secondary outcomes of a randomised controlled phase 3 trial
Pittet L, Messina N, McDonald E, Orsini F, Barry S, Bonten M, Campbell J, Croda J, Croda M, Dalcolmo M, Gardiner K, Gwee A, Jardim B, Lacerda M, Lucas M, Lynn D, Manning L, Perrett K, Post J, Prat-Aymerich C, Richmond P, Rocha J, Rodriguez-Baño J, Warris A, Wood N, Davidson A, Curtis N, Curtis N, Davidson A, Gardiner K, Gwee A, Jamieson T, Messina N, Morawakage T, Perlen S, Perrett K, Pittet L, Sastry A, Teo J, Orsini F, Lee K, Moore C, Vidmar S, Pittet L, Ali R, Dunn R, Edler P, Gell G, Goodall C, Hall R, Krastev A, La N, McDonald E, McPhate N, Nguyen T, Ren J, Stevens L, Messina N, Alamrousi A, Bonnici R, Dang T, Germano S, Hua J, McElroy R, Razmovska M, Reddiex S, Wang X, Anderson J, Azzopardi K, Bennett-Wood V, Czajko A, Mazarakis N, McCafferty C, Oppedisano F, Ortika B, Pell C, Spry L, Toh R, Velagapudi S, Vlahos A, Wee-Hee A, Ramos P, De La Cruz K, Gamage D, Karunanayake A, Mezzetti I, Ong B, Singh R, Sooriyarachchi E, Nicholson S, Cain N, Brizuela R, Huang H, Abruzzo V, Bealing M, Bimboese P, Bowes K, Burrell E, Chan J, Cushnahan J, Elborough H, Elkington O, Fahey K, Fernandez M, Flynn C, Fowler S, Andrit M, Gladanac B, Hammond C, Ma N, Macalister S, Milojevic E, Mojeed J, Nguyen J, O'Donnell L, Olivier N, Ooi I, Reynolds S, Shen L, Sherry B, Spotswood J, Wedderburn J, Younes A, Legge D, Bell J, Cheah J, Cobbledick A, Lim K, Elia S, Addlem L, Bourke A, Brophy C, Henare N, Jenkins N, Machingaifa F, Miller S, Mitchell K, Pitkin S, Wall K, Villanueva P, Crawford N, Pittet L, Norton W, Tan N, Chengodu T, Dawson D, Gordon V, Korman T, O'Bryan J, Abruzzo V, Agius S, Bannister S, Bucholc J, Burns A, Camesella B, Carlin J, Ciaverella M, Curtis M, Firth S, Guo C, Hannan M, Hill E, Joshi S, Lieschke K, Mathers M, Odoi S, Rak A, Richards C, Steve L, Stewart C, Sudbury E, Thomson H, Watts E, Williams F, Young A, Glenn P, Kaynes A, De Floy A, Buchanan S, Sondag T, Xie I, Edmund H, Byrne B, Keeble T, Ngien B, Noonan F, Wearing-Smith M, Clarke A, Davies P, Eastwood O, Ellinghaus A, Ghieh R, Hilton Z, Jennings E, Kakkos A, Liang I, Nicol K, O'Callaghan S, Osman H, Rajaram G, Ratcliffe S, Rayner V, Salmon A, Scheppokat A, Stevens A, Street R, Toogood N, Wood N, Bahaduri T, Baulman T, Byrne J, Carter C, Corbett M, Dao A, Desylva M, Dunn A, Gardiner E, Joyce R, Kandasamy R, Munns C, Pelayo L, Sharma K, Sterling K, Uren C, Colaco C, Douglas M, Hamilton K, Bartlett A, McMullan B, Palasanthiran P, Williams P, Beardsley J, Bergant N, Lagunday R, Overton K, Post J, Al-Hindawi Y, Barney S, Byrne A, Mead L, Plit M, Lynn D, Benson S, Blake S, Botten R, Chern T, Eden G, Griffith L, James J, Lynn M, Markow A, Sacca D, Stevens N, Wesselingh S, Doran C, Barry S, Sawka A, Evans S, Goodchild L, Heath C, Krieg M, Marshall H, McMillan M, Walker M, Richmond P, Amenyogbe N, Anthony C, Arnold A, Arrowsmith B, Ben-Othman R, Clark S, Dunnill J, Eiffler N, Ewe K, Finucane C, Flynn L, Gibson C, Hartnell L, Hollams E, Hutton H, Jarvis L, Jones J, Jones J, Jones K, Kent J, Kollmann T, Lalich D, Lee W, Lim R, McAlister S, McDonald F, Meehan A, Minhaj A, Montgomery L, O'Donnell M, Ong J, Ong J, Parkin K, Perez G, Power C, Rezazadeh S, Richmond H, Rogers S, Schultz N, Shave M, Skut P, Stiglmayer L, Truelove A, Wadia U, Wallace R, Waring J, England M, Latkovic E, Manning L, Herrmann S, Lucas M, Lacerda M, Andrade P, Barbosa F, Barros D, Brasil L, Capella A, Castro R, Costa E, de Souza D, Dias M, Dias J, Ferreira K, Figueiredo P, Freitas T, Furtado A, Gama L, Godinho V, Gouy C, Hinojosa D, Jardim B, Jardim T, Junior J, Lima A, Maia B, Marins A, Mazurega K, Medeiros T, Melo R, Moraes M, Nascimento E, Neves J, Oliveira M, Oliveira T, Oliveira I, Otsuka A, Paes R, Pereira H, Pereira G, Prado C, Queiroz E, Rodrigues L, Rodrigues B, Sampaio V, Santos A, Santos D, Santos T, Santos E, Sartim A, Silva A, Silva J, Silva E, Simão M, Soares C, Sousa A, Trindade A, Val F, Vasconcelos A, Vasconcelos H, Croda J, Abreu C, Almeida K, de Andrade C, Angelo J, de Araújo Arcanjo G, Arruda B, Ayala W, Barbosa A, Batista F, de Morais Batista F, de Jesus Costa M, Croda M, da Cruz L, Diogo R, Escobar R, Fernandes I, Figueiredo L, Gonçalves L, Lahdo S, dos Santos Lencina J, de Lima G, MEIRELES B, Moreira D, Muranaka L, de Oliveira A, de Oliveira K, de Oliveira M, de Oliveira R, dos Reis Pereira A, Puga M, Ramos C, da Rosa T, dos Santos K, dos Santos C, dos Santos D, Santos K, da Silva P, da Silva P, dos Santos Silva D, da Silva P, da Rosa Soares B, Sperotto M, Tadokoro M, Tsuha D, Vieira H, Dalcolmo M, da Paixão C, Castro G, Collopy S, da Costa Silva R, da Silveira S, Da-Cruz A, de Carvalho A, de Cássia Batista R, De Freitas M, de Oliveira Ferreira A, de Souza A, Doblas P, dos Santos A, dos Santos V, dos Santos Gomes D, Fortunato A, Gomes-Silva A, Gonçalves M, Meireless P, da Costa Carvalho E, do Couto Motta F, de Mendonça L, dos Santos Pandine G, Pereira R, Maia I, da Rocha J, Romano J, dos Santos G, da Silva E, de Siqueira M, Soares Á, Bonten M, Arroyo S, Besten H, Boon A, Brakke K, Janssen A, Koopmans M, Lemmens T, Leurink T, Prat-Aymerich C, Septer-Bijleveld E, Stadhouders K, Troeman D, van der Waal M, van Opdorp M, van Sluis N, Wolters B, Kluytmans J, Romme J, van den Bijllaardt W, van Mook L, van Rijen M, Filius P, Gisolf J, Greven F, Huijbens D, Hassing R, Pon R, Preijers L, van Leusen J, Verheij H, Boersma W, Brans E, Kloeg P, Molenaar-Groot K, Nguyen N, Paternotte N, Rol A, Stooper L, Dijkstra H, Eggenhuizen E, Huijs L, Moorlag S, Netea M, Pranger E, Taks E, Oever J, Heine R, Blauwendraat K, Meek B, Erkaya I, Harbech H, Roescher N, Peeters R, Riele M, Zhou C, Calbo E, Marti C, Palomares E, Porcuna T, Barriocanal A, Barriocanal A, Casas I, Dominguez J, Esteve M, Lacoma A, Latorre I, Molina G, Molina B, Rosell A, Vidal S, Barrera L, Bustos N, Calderón I, Campos D, Carretero J, Castellano A, Compagnone R, de Arellano E, de la Serna A, del Toro Lopez M, Espindola M, Gutierrez A, Hernandez A, Jiménez V, Moreno E, Navarrete N, Paño T, Rodríguez-Baño J, Tristán E, Villegas M, Garces A, Amo E, Guerrero R, Goikoetxea J, Jorge L, Perez C, Álvarez M, Cuadra M, de las Revillas Almajano F, Garcia P, Poderos T, Rico C, Sanchez B, Valero O, Vega N, Campbell J, Barnes A, Catterick H, Cranston T, Dawe P, Fletcher E, Fouracre L, Gifford A, Gow N, Kirkwood J, Martin C, McAnew A, Mitchell M, Newman G, O'Connell A, Onysk J, Quinn L, Rhodes S, Stone S, Symons L, Tripp H, Watkins D, Whale B, Harding A, Lockhart G, Sidaway-Lee K, Campbell J, Hilton S, Manton S, Webber-Rookes D, Winder R, Moore J, Bateman F, Gibbons M, Knight B, Moss J, Statton S, Studham J, Hall L, Moyle W, Venton T. Bacille Calmette-Guérin vaccination to prevent febrile and respiratory illness in adults (BRACE): secondary outcomes of a randomised controlled phase 3 trial. EClinicalMedicine 2024, 72: 102616. PMID: 38774675, PMCID: PMC11106519, DOI: 10.1016/j.eclinm.2024.102616.Peer-Reviewed Original ResearchBacille Calmette-Guerin vaccineBacille Calmette-GuerinRandomised controlled phase 3 trialControlled phase 3 trialPhase 3 trialIntention-to-treatRespiratory illnessBCG-DenmarkControl groupHealthcare workersDecreased all-cause mortalityRisk of severe diseasePresence of co-morbidityAssociated with protectionAll-cause mortalityEpisodes of illnessRespiratory infectionsIncreased riskHealthcare centresSecondary outcomesCo-morbiditySevere diseaseOff-target effectsSevere episodesVaccineTravel surveillance uncovers dengue virus dynamics and introductions in the Caribbean
Taylor-Salmon E, Hill V, Paul L, Koch R, Breban M, Chaguza C, Sodeinde A, Warren J, Bunch S, Cano N, Cone M, Eysoldt S, Garcia A, Gilles N, Hagy A, Heberlein L, Jaber R, Kassens E, Colarusso P, Davis A, Baudin S, Rico E, Mejía-Echeverri Á, Scott B, Stanek D, Zimler R, Muñoz-Jordán J, Santiago G, Adams L, Paz-Bailey G, Spillane M, Katebi V, Paulino-Ramírez R, Mueses S, Peguero A, Sánchez N, Norman F, Galán J, Huits R, Hamer D, Vogels C, Morrison A, Michael S, Grubaugh N. Travel surveillance uncovers dengue virus dynamics and introductions in the Caribbean. Nature Communications 2024, 15: 3508. PMID: 38664380, PMCID: PMC11045810, DOI: 10.1038/s41467-024-47774-8.Peer-Reviewed Original ResearchConceptsDengue virusDENV-3Rates of severe diseaseMosquito-borne viral diseasePublic health threatPattern of spreadSevere diseaseLocal surveillanceGenomic epidemiologyEpidemiological patternsVirus surveillanceSurveillanceHealth threatSerotypesDiseaseIncreased rateDengueViral diseasesVirusInfected travelersFrequent outbreaksInterim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024
DeCuir J, Payne A, Self W, Rowley E, Dascomb K, DeSilva M, Irving S, Grannis S, Ong T, Klein N, Weber Z, Reese S, Ball S, Barron M, Naleway A, Dixon B, Essien I, Bride D, Natarajan K, Fireman B, Shah A, Okwuazi E, Wiegand R, Zhu Y, Lauring A, Martin E, Gaglani M, Peltan I, Brown S, Ginde A, Mohr N, Gibbs K, Hager D, Prekker M, Mohamed A, Srinivasan V, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Chang S, Mallow C, Kwon J, Exline M, Columbus C, Vaughn I, Safdar B, Mosier J, Harris E, Casey J, Chappell J, Grijalva C, Swan S, Johnson C, Lewis N, Ellington S, Adams K, Tenforde M, Paden C, Dawood F, Fleming-Dutra K, Surie D, Link-Gelles R, Collaborators C, Collaborators C, Ghamande S, Gottlieb R, McNeal T, Raver C, Bender W, Fletcher L, Heaton P, Kane S, McEvoy C, Thapa S, Vazquez-Benitez G, Frosch A, Lamerato L, Ramesh M, Arnofer J, Ali H, Hopkins J, Crane B, Dandamudi P, Goddard K, Hansen J, Timbol J, Zerbo O, Allen K, Duszynski T, Fadel W, Rogerson C, Qadir N, Chavez C, Doyle B, Mayer D, Rao S, Rivas C, Johnson N, Baughman A, Lwin C, Rhoads J, Womack K, Dunne M, Ciesla A, Mak J, Najdowski M, Ray C. Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024. MMWR Morbidity And Mortality Weekly Report 2024, 73: 180-188. PMID: 38421945, PMCID: PMC10907041, DOI: 10.15585/mmwr.mm7308a5.Peer-Reviewed Original ResearchConceptsVaccine effectivenessEmergency departmentCOVID-19 vaccineCDC's Advisory CommitteeCOVID-19-associated hospitalizationUrgent careCOVID-19 vaccine dosesImmunocompetent adultsMedian intervalCase-control designVE estimatesVaccine doseImmunization PracticesTest-negativeSevere diseaseCDC recommendationsDoseVaccineHospitalVE networkCOVID-19CDCMonthsAdvisory CommitteeDays
2023
Geographic and Demographic Representation in Industry-Sponsored, US-Based Clinical Trials of Systemic Lupus Erythematosus Therapies
Skydel J, Ramachandran R, Suttiratana S, Ross J, Burns C, Wallach J. Geographic and Demographic Representation in Industry-Sponsored, US-Based Clinical Trials of Systemic Lupus Erythematosus Therapies. The Journal Of Rheumatology 2023, 51: jrheum.2023-0920. PMID: 38101910, PMCID: PMC10922605, DOI: 10.3899/jrheum.2023-0920.Peer-Reviewed Original ResearchCOVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched Controls in Singapore
Tan W, Tan J, Lim J, Tan R, Bin Lee A, Leong F, Lee S, Chai L, Tan T, Bin Abdul Malek M, Ong B, Lye D, Chiew C, Chng W, Lim S, Bharwani L, Tan I, Sundar R, Tan K. COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched Controls in Singapore. JAMA Oncology 2023, 9: 1221-1229. PMID: 37440245, PMCID: PMC10346511, DOI: 10.1001/jamaoncol.2023.2271.Peer-Reviewed Original ResearchConceptsIncidence rate ratiosCancer survivorsVaccine doseSevere diseaseCohort studyTreated patientsProspective multicenter observational cohort studyCompeting-risk regression analysisMulticenter observational cohort studyMatched controlsVaccine efficacyVaccine effectivenessRisk of poor outcomesWaning of vaccine effectivenessSevere COVID-19 disease outcomesMRNA vaccine doseRisk of deathObservational cohort studyMRNA-based vaccinesSocioeconomic statusSARS-CoV-2 DeltaRate ratiosCOVID-19 hospitalizationIncidence rateOmicron waveEggerthella lenta augments preclinical autoantibody production and metabolic shift mimicking senescence in arthritis
Balakrishnan B, Luckey D, Wright K, Davis J, Chen J, Taneja V. Eggerthella lenta augments preclinical autoantibody production and metabolic shift mimicking senescence in arthritis. Science Advances 2023, 9: eadg1129. PMID: 37656793, PMCID: PMC10854426, DOI: 10.1126/sciadv.adg1129.Peer-Reviewed Original ResearchConceptsRheumatoid arthritisSevere diseaseAugmented antibody responsesCD4 T cellsHumanized mouse modelOnset of symptomsCollagen-induced arthritisAssociated with several diseasesNaive miceT cellsAutoantibody productionFemale miceB cellsEtiology of rheumatoid arthritisInterleukin-17Genetic predispositionMouse modelRheumatoid factorAntibody responseIncreased CXCL5RA severityGut dysbiosisArthritisBile acidsEggerthella lentaAssociation Between COVID-19 Infection and Pulmonary Fibrosis: A Nested Case-Control Study
Najjar-Debbiny R, Barnett-Griness O, Khoury J, Gronich N, Weber G, Adir Y, Shteinberg M, Shneir S, Sharma L, Saliba W. Association Between COVID-19 Infection and Pulmonary Fibrosis: A Nested Case-Control Study. The American Journal Of Medicine 2023, 136: 1087-1093.e2. PMID: 37598922, DOI: 10.1016/j.amjmed.2023.07.020.Peer-Reviewed Original ResearchPulmonary fibrosisCase-control studyCOVID-19 severityCOVID-19Multivariable conditional logistic regression modelsNested Case-Control StudyConditional logistic regression modelsSevere COVID-19Prior COVID-19COVID-19 infectionLogistic regression modelsLargest healthcare providerUnderlying cohortCohort entrySignificant morbiditySurveillance biasOdds ratioSevere diseaseFibrosisHealthcare providersCoronavirus diseaseCalendar timePatientsCohortLag timeSpatiotemporally organized immunomodulatory response to SARS-CoV-2 virus in primary human broncho-alveolar epithelia
Castaneda D, Jangra S, Yurieva M, Martinek J, Callender M, Coxe M, Choi A, Diego J, Lin J, Wu T, Marches F, Chaussabel D, Yu P, Salner A, Aucello G, Koff J, Hudson B, Church S, Gorman K, Anguiano E, García-Sastre A, Williams A, Schotsaert M, Palucka K. Spatiotemporally organized immunomodulatory response to SARS-CoV-2 virus in primary human broncho-alveolar epithelia. IScience 2023, 26: 107374. PMID: 37520727, PMCID: PMC10374611, DOI: 10.1016/j.isci.2023.107374.Peer-Reviewed Original ResearchHuman air-liquid interface culturesAir-liquid interface culturesNucleoprotein expressionAirway epithelial cellsSARS-CoV-2 variant infectionResponse to virusesUnmet medical needCSF3 expressionInterface culturesImmune responseEpithelial cellsDay 4Severe diseaseVariant infectionBasal cellsTranscriptional signatureSARS-CoV-2InfectionApical cellsEarly responseMedical needSARS-CoV-2 virusEpitheliaVirusPost-infectionMulti-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients
Diray-Arce J, Fourati S, Jayavelu N, Patel R, Maguire C, Chang A, Dandekar R, Qi J, Lee B, van Zalm P, Schroeder A, Chen E, Konstorum A, Brito A, Gygi J, Kho A, Chen J, Pawar S, Gonzalez-Reiche A, Hoch A, Milliren C, Overton J, Westendorf K, Network I, Abraham J, Adkisson M, Albert M, Torres L, Alvarenga B, Anderson M, Anderson E, Arnett A, Asashima H, Atkinson M, Baden L, Barton B, Beach K, Beagle E, Becker P, Bell M, Bernui M, Bime C, Kumar A, Booth L, Borresen B, Brakenridge S, Bristow L, Bryant R, Calfee C, Manuel J, Carrillo S, Chak S, Chang I, Connors J, Conway M, Corry D, Cowan D, Croen B, Dela Cruz C, Cusimano G, Eaker L, Edwards C, Ehrlich L, Elashoff D, Erickson H, Erle D, Farhadian S, Farrugia K, Fatou B, Fernandes A, Fernandez-Sesma A, Fragiadakis G, Furukawa S, Geltman J, Ghale R, Bermúdez M, Goonewardene M, Sanchez E, Guirgis F, Hafler D, Hamilton S, Harris P, Nemati A, Hendrickson C, Agudelo N, Hodder T, Holland S, Hough C, Huerta C, Hurley K, Hutton S, Iwasaki A, Jauregui A, Jha M, Johnson B, Joyner D, Kangelaris K, Kelly G, Khalil Z, Khan Z, Kheradmand F, Kim J, Kimura H, Ko A, Kohr B, Kraft M, Krummel M, Kutzler M, Lasky-Su J, Lee S, Lee D, Leipold M, Lentucci C, Leroux C, Lin E, Liu S, Love C, Lu Z, Maliskova L, Roth B, Manohar M, Martens M, McComsey G, McEnaney K, McLin R, Melamed E, Melnyk N, Mendez K, Messer W, Metcalf J, Michelotti G, Mick E, Mohanty S, Mosier J, Mulder L, Murphy M, Nadeau K, Nelson E, Nelson A, Nguyen V, Oberhaus J, Panganiban B, Pellegrini K, Pickering H, Powell D, Presnell S, Pulendran B, Rahman A, Sadeed A, Raskin A, Reed E, Pereira S, Rivera A, Rogers J, Rogers A, Rogowski B, Rooks R, Rosenberg-Hasson Y, Rothman J, Rousseau J, Salehi-Rad R, Saluvan M, Samaha H, Schaenman J, Schunk R, Semenza N, Sen S, Sevransky J, Seyfert-Margolis V, Shaheen T, Shaw A, Sieg S, Siegel S, Sigal N, Siles N, Simmons B, Simon V, Singh G, Sinko L, Smith C, Smolen K, Song L, Srivastava K, Sullivan P, Syphurs C, Tcheou J, Tegos G, Tharp G, Ally A, Tsitsiklis A, Ungaro R, Vaysman T, Viode A, Vita R, Wang X, Ward A, Ward D, Willmore A, Woloszczuk K, Wong K, Woodruff P, Xu L, van Haren S, van de Guchte A, Zhao Y, Cairns C, Rouphael N, Bosinger S, Kim-Schulze S, Krammer F, Rosen L, Grubaugh N, van Bakel H, Wilson M, Rajan J, Steen H, Eckalbar W, Cotsapas C, Langelier C, Levy O, Altman M, Maecker H, Montgomery R, Haddad E, Sekaly R, Esserman D, Ozonoff A, Becker P, Augustine A, Guan L, Peters B, Kleinstein S. Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients. Cell Reports Medicine 2023, 4: 101079. PMID: 37327781, PMCID: PMC10203880, DOI: 10.1016/j.xcrm.2023.101079.Peer-Reviewed Original ResearchConceptsDisease courseFatal COVID-19 diseaseHospitalized COVID-19 patientsSevere disease courseCOVID-19 participantsCOVID-19 patientsTrajectory groupsHost immune responseCOVID-19 diseaseImmune correlatesAcute infectionClinical courseHospital admissionClinical outcomesFatal outcomeClinical prognosisImmune responseSevere diseaseLongitudinal bloodNasal samplesBiologic stateLongitudinal studyDistinct assaysCohortMolecular signaturesChanges in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022
Klaassen F, Chitwood M, Cohen T, Pitzer V, Russi M, Swartwood N, Salomon J, Menzies N. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. Clinical Infectious Diseases 2023, 77: 355-361. PMID: 37074868, PMCID: PMC10425195, DOI: 10.1093/cid/ciad210.Peer-Reviewed Original ResearchConceptsSevere diseasePopulation immunityOmicron infectionOmicron variantUS populationSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 infectionRespiratory syndrome coronavirus 2SARS-CoV-2 Omicron variantRestoration of immunitySyndrome coronavirus 2Bayesian evidence synthesis modelInfection-acquired immunityEvidence synthesis modelSARS-CoV-2Prior immunological exposureCoronavirus 2Additional infectionsImmunological exposureInfectionDiseaseImmunityVaccinationUnited StatesPsoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities
Blauvelt A, Gondo G, Bell S, Echeverría C, Schmitt-Egenolf M, Skov L, van de Kerkhof P, Howard L, Strober B. Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities. Journal Of Psoriasis And Psoriatic Arthritis 2023, 8: 100-106. PMID: 39296315, PMCID: PMC11361513, DOI: 10.1177/24755303231160683.Peer-Reviewed Original ResearchPsoriasis Area Severity IndexBody surface area involvementPatient-reported outcome measuresSurface area involvementDisease-specific qualityQuality of lifeExtensive psoriasisPsoriasis severityArea involvementPatient burdenOutcome measuresSevere diseaseClinical experienceSeverity IndexPsoriasisDiseasePresent studyPatientsSeverityO-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY
Idalsoaga F, Díaz L, Ayares G, Arnold J, Dunn W, Li Y, Singal A, Simonetto D, Ayala-Valverde M, Perez D, Gomez J, Escarate R, Fuentes-López E, Ramirez C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Waleed M, Stefanescu H, Horhat A, Bumbu A, Attar B, Grawal R, Cabezas J, García-Carrera I, Cuyàs B, Poca M, Pastor G, Sarin S, Maiwall R, Jalal P, La Tijera M, Kulkarni A, P N, Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jimenez C, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Arrese M, Shah V, Bataller R, Arab J. O-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY. Annals Of Hepatology 2023, 28: 101035. DOI: 10.1016/j.aohep.2023.101035.Peer-Reviewed Original ResearchCox regressionSevere AHCohort studyHigh mortalityAlcohol‐Associated HepatitisRetrospective cohort studyKaplan-Meier curvesShort-term mortalityGlobal cohort studyLille modelMultivariable analyzesCorticosteroid treatmentMELD scoreAH patientsSevere entitySerum bilirubinClinical variablesBetter prognosticationWorldwide cohortSevere diseasePatientsDay 7Predicting ResponseDay 4CorticosteroidsUse, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric‐Onset IBD Cohort
Kaplan J, Liu C, King E, Bass J, Patel A, Tung J, Chen S, Lissoos T, Candela N, Saeed S, Colletti R, Network I, Adler J, Baron H, Cabrera J, Dorsey J, Dykes D, Ebach D, Garin‐Laflam M, Gold B, Grunow J, Higuchi L, Jester T, Lapsia S, Leibowitz I, Linvlle T, Morhardt T, Moses J, Moulton D, Nasiri‐Blomgren S, Niklinska‐Schirtz B, Ogunmola N, Palomo P, Park K, Pashankar D, Pasternak B, Radano M, Samson C, Sandberg K, Schaefer M, Shashidhar H, Steiner S, Sullivan J, Tomer G, Verstraete S. Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric‐Onset IBD Cohort. Journal Of Pediatric Gastroenterology And Nutrition 2023, 76: 566-575. PMID: 36804501, PMCID: PMC10097486, DOI: 10.1097/mpg.0000000000003734.Peer-Reviewed Original ResearchConceptsCrohn's diseaseUlcerative colitisLoss of responseFirst biologicSubsequent biologicsBiologic agentsBiologic medicationsBiologic treatmentAnti-tumor necrosis factor agentsUpper gastrointestinal tract involvementGastrointestinal tract involvementNecrosis factor agentsActive Crohn's diseaseFirst biologic agentIBD cohortInitial biologicSecond biologicTract involvementCorticosteroid useFactor agentsPediatric IBDBiologic initiationDisease courseUnivariate analysisSevere diseaseThe impact of ABO and RhD blood types on Babesia microti infection
Jajosky R, O’Bryan J, Spichler-Moffarah A, Jajosky P, Krause P, Tonnetti L. The impact of ABO and RhD blood types on Babesia microti infection. PLOS Neglected Tropical Diseases 2023, 17: e0011060. PMID: 36696414, PMCID: PMC9901808, DOI: 10.1371/journal.pntd.0011060.Peer-Reviewed Original ResearchConceptsB. microti infectionABO blood typeBabesia microti infectionMicroti infectionBlood donorsBlood typeDisease severityPlasmodium falciparum malaria patientsFalciparum malaria patientsHigher peak parasitemiaRed blood cell antigensType BImpact of ABOBlood cell antigensBlood type BMalaria patientsTransfusion strategyInfected donorsRhD blood typeSevere diseasePeak parasitemiaB antigensCell antigensPossible associationRhD antigenCOVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation
Patton M, Orihuela C, Harrod K, Bhuiyan M, Dominic P, Kevil C, Fort D, Liu V, Farhat M, Koff J, Lal C, Gaggar A, Richter R, Erdmann N, Might M, Gaggar A. COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation. Critical Care 2023, 27: 34. PMID: 36691080, PMCID: PMC9868503, DOI: 10.1186/s13054-023-04312-0.Peer-Reviewed Original ResearchConceptsBacterial co-infectionNeutrophil-to-lymphocyte ratioIn-hospital mortalityMechanical ventilationICU admissionCo-infectionRisk factorsSARS-CoV-2 variantsCohort studyIncreased riskPrimary outcomeIncreased risk of in-hospital mortalityRisk of in-hospital mortalityCommunity-acquired bacteremiaCulture-positive resultsRetrospective cohort studySingle-center reportsInpatient encountersMultivariate logistic regressionBlood culturesPrognostic indicatorOmicron SARS-CoV-2 variantComparison cohortOdds ratioSevere disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply